Skip to main content
Home
  • Clinical Outcome Assessments
    Clinical Outcome Assessments

    What are Clinical Outcome Assessments (COAs)? What do they measure?

    Learn more about COAs
    hero_1.jpeg
    The most trusted distributor of COAs

    700+ exclusive COA distributions on behalf of their copyright owners

    hero_2.jpeg
    PROQOLID™: the largest COA database

    7,000+ COAs described in details and accessible in this unique database

  • Services
    Services

    Mapi Research Trust provides turnkey solutions for your Clinical Outcome Assessments (COAs) strategies - including COA databases, targeted literature reviews, licensing.

    Read More
    COA Databases Patient-Centered Endpoint Intelligence COA Licensing Translation and Linguistic Validation eCOA Licensing COA Repository
    hero_3.jpeg
    About ePROVIDE™

    Online access to all our services and COA databases

    hero_2_2.jpeg
    What are eBooklets?

    Find out more about this step-by-step guidance for valid digitization of COAs

  • Author Collaboration
    Author Collaboration

    Our team is dedicated to assisting authors in the daily management of their questionnaires and all derivatives, including translations and electronic versions

    Read More
    COA distribution COA copyright and protection Promotion of COAs and developers Testimonials
    hero_3_1.jpeg
    Catalog of COAs distributed by Mapi Research Trust

    800+ exclusive distributions of COAs, accessible in ePROVIDE

  • Resources
    Resources

    ACCESS all our resources on COAs and eCOA: webinars, publications, blogs. SUBSCRIBE to receive email updates.

    Read More
    Blog Publications Useful links Webinar recordings Whitepapers
    Whitepaper-Digitizing-COAs.jpg
    New whitepaper

    Digitizing COAs: A streamlined approach to approval

    hero_4_2.jpeg
    New whitepaper

    COAs and copyright: How to mitigate risks of infringement and misuse in clinical research and practice

  • News & Events
    News & Events

    Stay informed with our latest news and check all our upcoming events. SUBSCRIBE to get email updates.

    Read More
    hero_5_1.jpeg
    News
    Hero_5_2.jpeg
    Conferences
    Hero_5_3.jpeg
    Webinars
  • About us
    About us

    Mapi Research Trust is a non-profit organization dedicated to improving patients’ quality of life by facilitating access to Clinical Outcome Assessments(COAs).

    Read More
    hero_6_1.jpeg
    Team

    A global team of multi-disciplinary experts

    hero_6_2.jpeg
    Experience

    Collecting & Processing Patient Centered Outcomes information for more than two decades

  • Contact
  1. Home
  2. News & Events
  3. Events
  4. Webinars
  5. GHQ-12 (General Health Questionnaire): A validated psychiatric screener to quickly identify signs of distress

GHQ-12 (General Health Questionnaire): A validated psychiatric screener to quickly identify signs of distress

Watch the replay

  • Date 16 March 2023
    Time 11:00 - 12:00
    Location Webinar
    Timezone America/New York

    The General Health Questionnaire (GHQ) was designed to be a self-administered screening test aimed at detecting psychiatric disorders among respondents in community settings and non-psychiatric clinical settings, such as primary care or among general medical out-patients. It was designed to be easy to administer, acceptable to respondents, concise and objective in the sense that it did not require the person administering it to make subjective assessments about the respondent. It aimed at detecting those forms of psychiatric disorder which may have relevance to a patient’s presence in a medical clinic, so that its focus must be on psychological components of ill-health.

    The original experimental work upon which the GHQ was based sought to discover those features which distinguished psychiatric patients as a class from individuals in the community who considered themselves to be healthy. There are many ways in which psychiatric patients differ from one another but a screening questionnaire need not be concerned with such distinctions. The GHQ is specifically concerned with the hinterland between psychological sickness and psychological health.

    Since the questionnaire was designed to be useful in consulting settings it focuses on breaks in normal function, rather than upon lifelong traits. The questionnaire concerns itself with two major classes of phenomena: inability to continue to carry out one’s normal ‘healthy’ functions, and the appearance of new phenomena of a distressing nature. The test items were chosen so that they differentiate psychiatric patients as a class from non-cases as a class, and thus they are concentrated on the hinterland between the two classes rather than ranging along the whole continuum between normality and severe disturbance. Since the respondent is not asked how long he or she has experienced each symptom the GHQ therefore detects disorders of less than two weeks’ duration – none of which can be counted as ‘cases’ by the various research systems and most of which require symptoms to have been present for at least two weeks.

     

    Who should attend?

    This webinar will be of interest to:

    • Psychiatrists and Psychologists (both practicing clinicians and students).

    • Quality of Life (QoL) and Health Research project supervisors and administrators from pharmaceutical and bio-tech companies, universities, teaching hospitals, emergency services and the military.

    • Medical Doctors/General Practitioners.

     

    What you will learn

    • The GHQ-12 is a validated psychiatric screening instrument for clinicians and researchers to distinguish psychiatric disorders among respondents in community settings and non-psychiatric clinical settings.
    • It is available in many validated translations for use in multi-cultural environments.
    • The GHQ-12 and its other versions are copyrighted and can be easily obtained and licensed via the ePROVIDETM platform from Mapi Research Trust.

     

Watch the replay

 

Speakers

Tom Roberts

Emergency Medicine Doctor

Dr Tom Roberts is an Academic Emergency Medicine Doctor based in the UK. He established the UK’s largest Emergency Medicine research network, funded by the Royal College of Emergency Medicine.

He has extensive research experience and publications in the field of distress, trauma, and fatigue in frontline doctors. This research includes the use of self-administered research tools, including the General Health Questionnaire. His research has recruited almost 10,000 frontline Doctors since 2018. He also has publications in the field of acute headache, E-scooter injuries, and global health.

He continues to work as an Emergency Medicine Doctor in the Southwest of England. He is passionate about using his clinical work to improve care for all Emergency Care patients through research and the translation of this research into evidence-based care.

Frederique Boucher

Account Executive, Author Collaboration Unit, Mapi Research Trust

Frederique Boucher joined the Author Collaboration Unit at Mapi Research Trust in April 2021. Frederique establishes new collaborations with authors and copyright holders of Clinical Outcome Assessments and assists them with the daily management of their questionnaires. She manages European, Canadian, American and UK accounts including the management of the scales developed by GL Assessment. Prior to this, she has worked for the past 15 years in the linguistic validation of COAs at Mapi/ICON Language Services. She obtained a MA in Quadrilingual Translation & Interpreting, from Angers’ Catholic University.

Related information

Webpage

Access the Official GHQ in ePROVIDE

In this section
In this section
  • News
  • Events
    • Conferences
    • Webinars
Site Branding
    ICON plc
  • Contact
  • About Us
For Clients
  • Services
  • Resources
  • ePROVIDE™
News & Events
  • News
  • Conferences
  • Webinars
Socials
  • Linkedin

Legal Footer

  • © 2025 Mapi Research Trust
  • Disclaimer
  • Privacy
How can we help?
  • All
Popular search terms:
  • COVID-19
  • Site & Patient Recruitment
  • Oncology
  • Medical Device
  • Real World Evidence
  • Decentralised & hybrid clinical trials
  • Digital Disruption